JP2007505922A5 - - Google Patents

Download PDF

Info

Publication number
JP2007505922A5
JP2007505922A5 JP2006527059A JP2006527059A JP2007505922A5 JP 2007505922 A5 JP2007505922 A5 JP 2007505922A5 JP 2006527059 A JP2006527059 A JP 2006527059A JP 2006527059 A JP2006527059 A JP 2006527059A JP 2007505922 A5 JP2007505922 A5 JP 2007505922A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
amino
acyloxy
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006527059A
Other languages
English (en)
Japanese (ja)
Other versions
JP4943845B2 (ja
JP2007505922A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/030506 external-priority patent/WO2005028436A2/en
Publication of JP2007505922A publication Critical patent/JP2007505922A/ja
Publication of JP2007505922A5 publication Critical patent/JP2007505922A5/ja
Application granted granted Critical
Publication of JP4943845B2 publication Critical patent/JP4943845B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006527059A 2003-09-17 2004-09-17 サリドマイド類似体 Expired - Fee Related JP4943845B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50472403P 2003-09-17 2003-09-17
US60/504,724 2003-09-17
PCT/US2004/030506 WO2005028436A2 (en) 2003-09-17 2004-09-17 Thalidomide analogs as tnf-alpha modulators

Publications (3)

Publication Number Publication Date
JP2007505922A JP2007505922A (ja) 2007-03-15
JP2007505922A5 true JP2007505922A5 (cg-RX-API-DMAC7.html) 2007-10-11
JP4943845B2 JP4943845B2 (ja) 2012-05-30

Family

ID=34375538

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006527059A Expired - Fee Related JP4943845B2 (ja) 2003-09-17 2004-09-17 サリドマイド類似体

Country Status (9)

Country Link
US (2) US7973057B2 (cg-RX-API-DMAC7.html)
EP (1) EP1663223B1 (cg-RX-API-DMAC7.html)
JP (1) JP4943845B2 (cg-RX-API-DMAC7.html)
CN (1) CN1867331B (cg-RX-API-DMAC7.html)
AU (1) AU2004274474B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414497A (cg-RX-API-DMAC7.html)
CA (2) CA2538864C (cg-RX-API-DMAC7.html)
SG (1) SG133603A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005028436A2 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2929331B2 (ja) * 1990-07-18 1999-08-03 丸善石油化学株式会社 トラクションドライブ用流体
CN101119969B (zh) 2004-07-15 2014-04-09 阿尔巴尼分子研究公司 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用
CN100383139C (zh) * 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2,6-二酮衍生物
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
US20080064876A1 (en) * 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
JP5523831B2 (ja) * 2006-08-30 2014-06-18 セルジーン コーポレイション 5−置換イソインドリン化合物
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
AU2013260742B2 (en) * 2007-03-20 2016-06-16 Celgene Corporation 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
AU2008229383B2 (en) 2007-03-20 2013-09-05 Celgene Corporation 4'-O-substituted isoindoline derivatives and compositions comprising and methods of using the same
US7723301B2 (en) * 2007-08-29 2010-05-25 The Board Of Trustees Of The University Of Arkansas Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
JP2012526823A (ja) 2009-05-12 2012-11-01 アルバニー モレキュラー リサーチ, インコーポレイテッド アリール、ヘテロアリール、および複素環置換テトラヒドロイソキノリンならびにそれらの使用
JP5764553B2 (ja) * 2009-05-12 2015-08-19 アルバニー モレキュラー リサーチ, インコーポレイテッド 7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンおよびその使用
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
LT3202461T (lt) * 2010-02-11 2019-04-25 Celgene Corporation Arilmetoksiizoindolino dariniai ir juos apimančios kompozicijos bei jų panaudojimo būdai
JP5857043B2 (ja) * 2010-06-18 2016-02-10 大鵬薬品工業株式会社 Prpk−tprkbモジュレーター及びその使用
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
JP2015500001A (ja) 2011-12-14 2015-01-05 大鵬薬品工業株式会社 組換えprpk−tprkb及びその使用
US9383644B2 (en) 2014-09-18 2016-07-05 Heraeus Precious Metals North America Daychem LLC Sulfonic acid derivative compounds as photoacid generators in resist applications
PT3214081T (pt) 2014-10-30 2020-08-31 Kangpu Biopharmaceuticals Ltd Derivado de isoindolina, seu intermediário, seu método de preparação, sua composição farmacêutica e sua utilização
US9477150B2 (en) 2015-03-13 2016-10-25 Heraeus Precious Metals North America Daychem LLC Sulfonic acid derivative compounds as photoacid generators in resist applications
WO2017007577A1 (en) * 2015-07-08 2017-01-12 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder, gait and limb impairment treatment
KR102838444B1 (ko) 2015-09-30 2025-07-24 더 유니버시티 코트 오브 더 유니버시티 오브 애버딘 탈리도마이드 유사체 및 사용 방법
MX2022008085A (es) * 2016-03-16 2022-07-11 H Lee Moffitt Cancer Ct & Res Moleculas peque?as contra cereblon para mejorar la funcion efectora de los linfocitos t.
JP7143295B2 (ja) * 2016-11-24 2022-09-28 ティアンジン ヘメイ ファーマスーティカル サイ-テック カンパニー リミテッド ピペリジン-2,6-ジオン誘導体及びクローン病の治療
CA3079407A1 (en) 2017-10-18 2019-04-25 Novartis Ag Compositions and methods for selective protein degradation
PE20210184A1 (es) 2018-07-11 2021-02-02 H Lee Moffitt Cancer Ct & Res Compuestos inmunomoduladores dimericos contra mecanismos basados en cereblon
US11324731B2 (en) 2018-09-13 2022-05-10 City Of Hope TXNIP-TRX complex inhibitors and methods of using the same
CA3119343C (en) 2018-11-13 2024-01-16 Biotheryx, Inc. Substituted isoindolinones
CN111601789A (zh) * 2018-12-20 2020-08-28 江苏凯迪恩医药科技有限公司 一种含氮杂环化合物、其制备方法及应用
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
CN114641337A (zh) * 2019-08-27 2022-06-17 密歇根大学董事会 Cereblon e3连接酶抑制剂
KR102783667B1 (ko) 2019-10-24 2025-03-21 삼성전자 주식회사 전자 장치 및 그의 디스플레이 동작 제어 방법
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
TW202140448A (zh) * 2020-01-16 2021-11-01 大陸商江蘇恆瑞醫藥股份有限公司 並環醯亞胺類衍生物、其製備方法及其在醫藥上的應用
AU2021226514B2 (en) * 2020-02-25 2023-10-19 Shanghaitech University Glutarimide skeleton-based compounds and application thereof
KR20220055171A (ko) * 2020-10-26 2022-05-03 주식회사 아이비스바이오 포말리도마이드로부터 3,6'-디티오포말리도마이드를 선택적으로 합성하는 방법
US20240166647A1 (en) * 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
EP4484418A1 (en) 2022-02-25 2025-01-01 Aevis Bio, Inc. Use of novel pomalidomide derivative for treating brain disease
TW202434562A (zh) 2022-11-04 2024-09-01 美商必治妥美雅史谷比公司 化合物及其用於治療血紅素病變之用途
CN119654316A (zh) * 2023-07-14 2025-03-18 标新生物医药科技(上海)有限公司 基于硫代的戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830991A (en) 1954-05-17 1958-04-15 Gruenenthal Chemie Products of the amino-piperidine-2-6-dione series
GB962857A (en) 1961-12-04 1964-07-08 Distillers Co Yeast Ltd Process for the production of imides
GB1049283A (en) * 1962-04-14 1966-11-23 Distillers Co Yeast Ltd Substituted butyro-lactones and -thiolactones
US3320270A (en) * 1963-10-08 1967-05-16 Tri Kem Corp Certain 2-acylimidothiazole compounds
US3314953A (en) 1964-03-16 1967-04-18 Richardson Merrell Inc 1-substituted-3-phthalimido-2, 5-dioxopyrrolidines
US3560495A (en) 1965-05-08 1971-02-02 Ernst Frankus 1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6
IL25595A (en) 1965-05-08 1971-01-28 Gruenenthal Chemie New history of cyclic amide compounds and process for the production of these compounds
GB1324718A (en) * 1970-11-10 1973-07-25 Nehezvegyipari Kutato Intezet Phthalimido triazines
US4067718A (en) 1975-11-12 1978-01-10 American Cyanamid Company Method for controlling the relative stem growth of plants
US4291048A (en) 1978-07-06 1981-09-22 Joseph Gold Method of treating tumors and cancerous cachexia with L-tryptophan
US5354690A (en) 1989-07-07 1994-10-11 Karl Tryggvason Immunological methods for the detection of the human type IV collagen α5 chain
US5902790A (en) 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
GB9311281D0 (en) 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
ES2098505T3 (es) 1991-04-17 1997-05-01 Gruenenthal Chemie Nuevos derivados de la talidomida, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
US6096768A (en) 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5443824A (en) 1994-03-14 1995-08-22 Piacquadio; Daniel J. Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
DE4422237A1 (de) 1994-06-24 1996-01-04 Gruenenthal Gmbh Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
AU696817B2 (en) 1994-12-30 1998-09-17 Celgene Corporation Immunotherapeutic imides/amides and their use for reducing levels of TNF alpha
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5783605A (en) 1995-02-27 1998-07-21 Kuo; Sheng-Chu Helper inducers for differentiation therapy and chemoprevention of cancer
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
CA2251060C (en) 1996-04-09 2006-09-12 Grunenthal Gmbh Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
DE19613976C1 (de) 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
AU3224997A (en) 1996-05-29 1998-01-05 Prototek, Inc Prodrugs of thalidomide and methods for using same as modulators of t-cell function
CA2624949C (en) 1996-07-24 2011-02-15 Celgene Corporation Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
AU746713B2 (en) 1996-11-05 2002-05-02 Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
AU5597098A (en) 1996-12-13 1998-07-03 Eli Lilly And Company Inhibitors of the enzymatic activity of psa
DE19703763C1 (de) 1997-02-01 1998-10-01 Gruenenthal Gmbh Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione
RU2108786C1 (ru) 1997-09-15 1998-04-20 Клавдия Степановна Евланенкова Средство для лечения онкологических больных
DE19743968C2 (de) 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen
EP1091726A2 (en) 1998-05-11 2001-04-18 EntreMed, Inc. Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
TR200003355T2 (tr) 1998-05-15 2001-03-21 Astrazeneca Ab Sitokinin sebep olduğu hastalıkların tedavisinde benzamid türevlerinin kullanılması
DE19843793C2 (de) 1998-09-24 2000-08-03 Gruenenthal Gmbh Substituierte Benzamide
US20030013739A1 (en) 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
ATE235256T1 (de) 1999-03-31 2003-04-15 Gruenenthal Gmbh Stabile wässrige lösung von 3-(1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin-2,6-dion
AU4515001A (en) 1999-12-02 2001-06-18 Regents Of The University Of Michigan, The Compositions and methods for locally treating inflammatory diseases
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
PT1353672E (pt) 2000-11-30 2008-01-11 Childrens Medical Center Síntese da 4-amino talidomida enantiómeros
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
EP1389203B8 (en) * 2001-02-27 2010-03-10 The Governement of the United States of America, represented by The Secretary Department of Health and Human services Analogs of thalidomide as angiogenesis inhibitors
AU2002323063B2 (en) 2001-08-06 2007-11-08 Entremed, Inc. Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CA2752140A1 (en) 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
CN100488959C (zh) 2003-03-27 2009-05-20 天津和美生物技术有限公司 水溶性的酞胺哌啶酮衍生物
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors

Similar Documents

Publication Publication Date Title
JP2007505922A5 (cg-RX-API-DMAC7.html)
TWI354666B (en) Heterocyclic aspartyl protease inhibitors
RU2005137403A (ru) Новые замещенные 3-сера-индолы
JP2005535586A5 (cg-RX-API-DMAC7.html)
JP2007519695A5 (cg-RX-API-DMAC7.html)
JP2018511587A5 (cg-RX-API-DMAC7.html)
RU2007118632A (ru) Ингибиторы митотического кинезина и способы их использования
RU2005136368A (ru) Производные пиперазина и их применение для лечения неврологических и психиатрических заболеваний
JP2005504039A5 (cg-RX-API-DMAC7.html)
RU2012134306A (ru) Азотосодержащие производные гетероарилов
RU2008126391A (ru) Производные 1,5-замещенного индол-2-иламида
JP2005526076A5 (cg-RX-API-DMAC7.html)
JP2006524222A5 (cg-RX-API-DMAC7.html)
JP2005538955A5 (cg-RX-API-DMAC7.html)
RU2005104434A (ru) Производные 1-гетероциклилалкил-3-сульфонилиндола или - индазола как лиганды 5-гидрокситриптамина-6
JP2002534519A5 (cg-RX-API-DMAC7.html)
JP2005518414A5 (cg-RX-API-DMAC7.html)
JP2011527686A5 (cg-RX-API-DMAC7.html)
RU2219179C2 (ru) Азациклические соединения, фармацевтические композиции
RU2007124545A (ru) Производные [4-(гетероарил)пиперазин-1-ил]-(2,5-замещенный фенил)метанона в качестве ингибиторов переносчика глицина-1 (glyt-1) для лечения неврологических и психоневрологических заболеваний
RU2000105266A (ru) Производные 1-(n-фениламиноалкил)-пиперазина, замещенные в положении 2 фенильного кольца
JP2002030084A5 (cg-RX-API-DMAC7.html)
JP2002505286A5 (cg-RX-API-DMAC7.html)
RU2005117374A (ru) Индолы, полезные для лечения заболеваний, связанных с андрогеновыми рецепторами
RU2006125748A (ru) Ингибиторы сомт